Protalex Inc. Announces John E. Doherty, Founder and Former CEO to Step Down From Board of Directors at End of Current Term

Aug 24, 2005, 01:00 ET from Protalex Inc.

    NEW HOPE, Pa., Aug. 24 /PRNewswire-FirstCall/ -- Protalex Inc.
 (OTC Bulletin Board:   PRTX) announced today that John E. Doherty, the Company's
 founder and former CEO will step down after serving out his current term on
 the Board of Directors.  Doherty, who was first to postulate that Protein A
 could have therapeutic effects in humans, was responsible for raising the
 initial capital to carry out the first successful proof of concept studies in
 animal models.  Doherty then went on to recruit the current management and
 scientific team which filed its' first IND in March 2005.  He leaves to devote
 more time to his other business ventures.
     "I am confident that Protalex, under the direction of Kirk Raab, Chairman
 of the Board, and Steve Kane, President and Chief Executive Officer, will go
 on to achieve great success over the coming years" said Doherty.  "They
 continue to attract the highest quality people to the organization and are
 well positioned for the future."
     "John was instrumental in keeping the company focused and on track in the
 early days" said Steve Kane.  "His keen insight and strategic vision will be
 missed, but I know that with his sincere passion for the Protalex mission,
 he'll always remain available to contribute to the Company's success."
     About Protalex
     Protalex is a biotechnology company engaged in the development of a new
 class of drug for the treatment of Rheumatoid Arthritis, Pemphigus and other
 autoimmune diseases.
     Cautionary Statement Regarding Forward Looking Information
     This release contains forward-looking information about Protalex, Inc.
 that are intended to be covered by the safe harbor forward-looking statements
 provided by the Private Securities Litigation Reform Act of 1995.  Forward-
 looking statements are statements that are not historical facts.  These
 statements can be identified by the use of forward-looking terminology such as
 "believe," "expect," "may," "will," "should,'' "project," "plan,'' "seek,"
 "intend,'' or "anticipate'' or the negative thereof or comparable terminology,
 and include discussions of strategy, and statements about industry trends and
 Protalex's future performance, operations and products.
     This forward-looking information should be considered only in connection
 with "Risk Factors" in Protalex's Registration Statement on Form SB-2 filed
 with the Securities and Exchange Commission ("SEC") on June 16, 2005 and its
 other periodic reports filed with the SEC.  Protalex assumes no obligation to
 update any forward-looking statements or information set forth in this press

SOURCE Protalex Inc.